These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38150745)

  • 21. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study.
    Morenas-Rodríguez E; Li Y; Nuscher B; Franzmeier N; Xiong C; Suárez-Calvet M; Fagan AM; Schultz S; Gordon BA; Benzinger TLS; Hassenstab J; McDade E; Feederle R; Karch CM; Schlepckow K; Morris JC; Kleinberger G; Nellgard B; Vöglein J; Blennow K; Zetterberg H; Ewers M; Jucker M; Levin J; Bateman RJ; Haass C;
    Lancet Neurol; 2022 Apr; 21(4):329-341. PubMed ID: 35305339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau accumulation and atrophy predict amyloid independent cognitive decline in aging.
    Fonseca CS; Baker SL; Dobyns L; Janabi M; Jagust WJ; Harrison TM
    Alzheimers Dement; 2024 Apr; 20(4):2526-2537. PubMed ID: 38334195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
    Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
    Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses.
    Rouch L; Virecoulon Giudici K; Cantet C; Guyonnet S; Delrieu J; Legrand P; Catheline D; Andrieu S; Weiner M; de Souto Barreto P; Vellas B;
    Am J Clin Nutr; 2022 Dec; 116(6):1492-1506. PubMed ID: 36253968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociable influences of
    Ge T; Sabuncu MR; Smoller JW; Sperling RA; Mormino EC;
    Neurology; 2018 May; 90(18):e1605-e1612. PubMed ID: 29592889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.
    Ben Bouallègue F; Mariano-Goulart D; Payoux P;
    Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
    Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
    JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.
    Toledo JB; Habes M; Sotiras A; Bjerke M; Fan Y; Weiner MW; Shaw LM; Davatzikos C; Trojanowski JQ;
    J Alzheimers Dis; 2019; 69(3):783-793. PubMed ID: 31127775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Emerging β-Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.
    Farrell ME; Papp KV; Buckley RF; Jacobs HIL; Schultz AP; Properzi MJ; Vannini P; Hanseeuw BJ; Rentz DM; Johnson KA; Sperling RA
    Neurology; 2022 Apr; 98(15):e1512-e1524. PubMed ID: 35338074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroinflammation and amyloid deposition in the progression of mixed Alzheimer and vascular dementia.
    Ying C; Kang P; Binkley MM; Ford AL; Chen Y; Hassenstab J; Wang Q; Strain J; Morris JC; Lee JM; Benzinger TLS; An H
    Neuroimage Clin; 2023; 38():103373. PubMed ID: 36933348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Cortical and Subcortical β-Amyloid With Standardized Measures of Depressive and Anxiety Symptoms in Adults Without Dementia.
    Krell-Roesch J; Syrjanen JA; Rakusa M; Vemuri P; Machulda MM; Kremers WK; Mielke MM; Lowe VJ; Jack CR; Knopman DS; Stokin GB; Petersen RC; Vassilaki M; Geda YE
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):64-71. PubMed ID: 33086924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.
    Weigand SD; Vemuri P; Wiste HJ; Senjem ML; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Jack CR;
    Alzheimers Dement; 2011 Mar; 7(2):133-41. PubMed ID: 21282074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
    Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
    JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.